# Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

> **NCT02706015** · PHASE3 · WITHDRAWN · sponsor: **Ache Laboratorios Farmaceuticos S.A.**

## Conditions studied

- Migraine Headache

## Interventions

- **DRUG:** Cefaliv® & Placebo
- **DRUG:** Neosaldina® & Placebo

## Key facts

- **NCT ID:** NCT02706015
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2021-05
- **Final completion:** 2021-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic reasons of the company
- **Last updated:** 2019-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706015, "Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02706015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*